Arvinas, Inc(NASDAQ:ARVN) 
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical tri...
Website: http://www.arvinas.com
Founded: 2013
Full Time Employees: 133
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 6.68
H 6.80
L 6.24
C 6.56
V 3,087,497
10EMA 6.56
20EMA 6.56
60EMA 6.56
120EMA 6.56
250EMA 6.56